February 20, 2012 -- Swift Biosciences, Inc. today announced their new line of myT™ Primer reagents for the detection of key cancer mutations. myT Primers provide an increased level of confidence and convenience in qPCR assays. Swift’s reagents have unique structural and thermodynamic properties that enable highly sensitive mismatch discrimination. The extreme selectivity and reproducibility of myT Primers results in an assay that gives a definitive Yes/No answer and eliminates the need to use a delta Ct method to call a result.
myT BRAF, the first product in the myT Primer line, is now available directly from Swift. myT BRAF can detect 1% mutant BRAF V600E/K present in a background of 103 wild-type genomic DNA copies with no breakthrough amplification from wild-type. myT BRAF performs well with either FFPE or fresh frozen samples. Each myT BRAF package includes sufficient reagents to assess up to 28 samples plus a positive and a negative control.
Additional myT Primer reagents will be coming soon, including myT BRAF–Ultra, an ultrasensitive version that provides 0.01% sensitivity—even single copy capability—with very low breakthrough amplification from wild-type. This level of sensitivity makes myT BRAF-Ultra ideal for use when the sample material is limiting or where the target is present at very low concentration, such as with circulating tumor cells (CTCs), serum, plasma and needle biopsies. Swift is also developing a set of myT KRAS primers for high sensitivity detection of mutations in codons 12 and 13.
To learn more about the power of myT Primers and how they can improve your assay or myT BRAF, please go to www.swiftbiosci.com.
